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Abstract
The generation of bradykinin (BK; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) in blood and kallidin (Lys-BK) in tissues by the action 
of the kallikrein-kinin system has received little attention in non-mammalian vertebrates. In mammals, kallidin can be generated 
by the coronary endothelium and myocytes in response to ischemia, mediating cardioprotective events. The plasma of birds 
lacks two key components of the kallikrein-kinin system: the low molecular weight kininogen and a prekallikrein activator analo-
gous to mammalian factor XII, but treatment with bovine plasma kallikrein generates ornitho-kinin [Thr6,Leu8]-BK. The possible 
cardioprotective effect of ornitho-kinin infusion was investigated in an anesthetized, open-chest chicken model of acute coronary 
occlusion. A branch of the left main coronary artery was reversibly ligated to produce ischemia followed by reperfusion, after 
which the degree of myocardial necrosis (infarct size as a percent of area at risk) was assessed by tetrazolium staining. The iv 
injection of a low dose of ornitho-kinin (4 µg/kg) reduced mean arterial pressure from 88 ± 12 to 42 ± 7 mmHg and increased 
heart rate from 335 ± 38 to 402 ± 45 bpm (N = 5). The size of the infarct was reduced by pretreatment with ornitho-kinin (500 
µg/kg infused over a period of 5 min) from 35 ± 3 to 10 ± 2% of the area at risk. These results suggest that the physiological 
role of the kallikrein-kinin system is preserved in this animal model in spite of the absence of two key components, i.e., low 
molecular weight kininogen and factor XII.
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The kallikrein-kinin system (KKS) consists of a phylo-
genetically ancient cascade that includes substrates (kinin-
ogens), proteases (kallikreins), biologically active peptides 
(kinins), peptidases (kininases), and kinin receptors. In 
mammals, the plasma KKS is part of the so-called “con-
tact” system, that becomes activated when blood contacts 
surface materials (contact activation). The contact system 
consists of the zymogens factor XII (FXII), factor XI (FXI), 
plasma prekallikrein (PK), and the nonenzymatic cofactor 
high molecular weight kininogen (HK). Once activated, 
activated factor XII (FXIIa) can activate three central sub-
stances that trigger different pathways: FXI, that triggers 
blood coagulation, PK, that leads to the release of bradykinin 
(BK; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) from HK, and 
C1 esterase, that triggers the complement system (1). 
Another key enzyme of the KKS is tissue kallikrein 
(TK), an intracellular enzyme that is released and cleaves 
low molecular weight kininogen (LK), releasing Lys-BK (1). 
A number of observations have focused on Lys-BK as a 
potential mediator of endogenous cardiovascular protective 
mechanisms. This is due to the fact that KKS components 
are localized in the heart and in the vascular tissues (1-4). 
Lys-BK is released during ischemia, causing beneficial 
cardiac effects and contributing to the cardioprotective 
effects of preconditioning (2-4). Lys-BK reduces arteriolar 
resistance after triggering several downstream events via 
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activation of B2 receptors, a seven-transmembrane G-
protein-coupled receptor on endothelial cells, and initiating 
prostacyclin synthesis, with the formation of nitric oxide and 
smooth muscle hyperpolarization factor (1,2).
Recently, there has been renewed interest in FXII and the 
KKS. Data from animal models strongly suggest that these 
proteins play a decisive role in pathological thrombus forma-
tion in mammals. Genetically altered animals have been used 
strategically to study the physiological and pathological roles 
of several constituents of the KKS. In particular, knock-out 
mice genetically deficient in BK B2 receptor, HK, and FXII 
have shown delayed thrombus formation (5-9).
The avian KKS differs significantly from the mam-
malian KKS. A recent study has shown that a single gene 
corresponding to the evolutionary predecessor of FXI and 
PK occurs in chickens, but the predecessor of FXII is not 
present in the genome (10). Accordingly, FXII activity cannot 
be detected in avian plasma by the classical methodology 
(11-14), whereas three other constituents of the KKS, i.e., 
HK (15), PK (16) and TK (17), have been described in this 
animal species. Ischemic heart damage can be reduced 
in birds by ischemic preconditioning (18). Whether protec-
tion against cardiac ischemic damage in birds depends 
on kinins is not known. Treatment of avian HK with bovine 
PK generates a BK-like substance, denoted ornitho-kinin 
[Thr6,Leu8]-BK (OK). Whether OK protects against ischemic 
damage in birds is not known. 
By studying the possible cardioprotection elicited by OK 
in an animal model of acute ischemia-reperfusion injury, the 
natural deficiency of LK provides the opportunity to identify 
the importance of this substrate in the physiological role of 
the KKS. Our objective was to determine whether the OK 
receptor is functional in this cardiovascular system by using 
a Langendorff preparation and an open-chest method to 
assay its vasodilator and cardioprotective effects against 
ischemia-reperfusion injury, respectively.
Material and Methods 
Animals and care
All procedures involving animals and their care were 
conducted in accordance with the Guidelines for the Use 
of Animals in Biochemical Research (19). This study was 
approved by the Comissão de Ética no Uso de Animais do 
Instituto Butantan (CEUAIB, protocol No. 189/04). 
Drugs 
Bradykinin, captopril and 2,3,5-triphenyltetrazolium 
chloride were purchased from Sigma Aldrich Co. (USA), 
salts from Merck (Germany), sodium heparin (Liquemine) 
from Roche Laboratories (Brazil), and diazepam from Cris-
talia (Brazil). Sodium pentobarbital was a gift from Abbott 
Laboratories (Brazil). Ornitho-kinin ([Thr6,Leu8]-bradykinin) 
(purity >95% in high performance liquid chromatography; 
gradient system 5-100% in 25 min. A = 0.1% trifluoroacetic 
acid (TFA); B = acetonitrile with 0.1% TFA) was synthe-
sized by the Laboratory of Applied Toxicology of Instituto 
Butantan (Brazil).
Effect of iv ornitho-kinin on mean arterial blood pressure
Chickens were anesthetized with a mixture of sodium 
pentobarbital and chloral hydrate (equithesin, 2.5 mL/kg 
body weight), injected deeply into the pectoral musculature 
(20). The left brachial vein was cannulated with polyethylene 
(PE50) tubing and connected to a pressure transducer for 
drug administration. Data were recorded with a data acquisi-
tion system (Biopac Systems, Inc., USA). OK and BK were 
injected into the brachial vein as a bolus at doses of 1, 2, 
4, 8, 16, 32, and 64 µg/kg. Captopril was then injected (0.1 
mg/kg, iv) and the responses to OK were measured again. 
This dose of captopril inhibits by 50% the breakdown of BK 
by the angiotensin-converting enzyme in mammals (21).
Measurement of ornitho-kinin-induced coronary 
vasodilation 
An adaptation of the Langendorff preparation suitable for 
the chicken heart (22) was used. Five birds were anesthe-
tized with equithesin and diazepam. Feathers were plucked 
from the skin on the medial surface of the wing, and 1000 
IU sodium heparin was given through the left brachial vein 
to prevent blood coagulation. After thoracotomy, the heart 
and the brachiocephalic trunk were removed. The aorta was 
placed quickly on the cannula of the perfusion apparatus, 
and perfusion of the coronary circulation was started within 
1 min after section of the carotid arteries. Perfusion pres-
sure was measured from a port in the cannula within 10 mm 
of the coronary ostia. Hearts were perfused retrogradely 
with Krebs-Henseleit solution (6.71 g/L NaCl, 1.08 g/L KCl, 
0.37 g/L CaCl2.H2O, 2.10 g/L NaHCO3, 0.16 g/L KH2PO4, 
0.10 g/L MgCl2.6H2O, and 2.30 g/L glucose) with 6.25 g/L 
dextran. The solution was gassed with 95% O2, 5% CO2 
and warmed to 40°C. pH was maintained between 7.38 
and 7.40 by adjustment of the flow rate of CO2 through 
the oxygenator. Coronary flow rate was adjusted to 13 mL/
min, about 5% of the cardiac output for the live bird. Since 
pump flow was fixed, changes in perfusion pressure were 
indicative of alterations in coronary resistance. Changes 
in perfusion pressure were measured with a pressure 
transducer, coupled to a recording system (PowerLab/4SP, 
AD Instruments, USA). Ventricular pressure and rate were 
recorded from a fluid-filled balloon tied into the left ventricle 
(isovolumic heart). Increasing doses of OK (1, 2, 4, 8, 16, 
32, 64, 128, 256, 512 ng) were injected as a bolus into a 
port of the perfusion apparatus close to the coronary ostia. 
Subsequent injections were made only after blood pressure 
returned to baseline.
Hemodynamic changes induced by coronary artery 
occlusion and reperfusion
Chickens were anesthetized with equithesin. The left 
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brachial vein was cannulated with PE50 tubing for ad-
ministration of diazepam (2.5 mg/kg). Additional doses of 
diazepam (1 mg/kg, iv) were given when noxious pinching 
induced withdrawal reflexes. The corneal/palpebral reflex 
remained present during the experiment. 
The right brachial artery was cannulated with PE50 
tubing for continuous mean arterial pressure and heart 
rate recordings. A PE50 catheter was inserted into the right 
external jugular vein and the tip was advanced to the right 
atrium for drug infusion. The animal was tracheotomized 
and ventilated artificially with room air (TOPO Dual mode 
Ventilator, Kent Scientific Corp., USA). Initial ventilation 
was 25 inflations/min (500-1000 mL/min). Arterial pH was 
maintained between 7.35 to 7.45, PCO2 between 20 and 
40 mmHg, and PO2 between 90 and 135 mmHg by supple-
menting the inspired air with 95% O2 or with 5% CO2 and 
changing the rate of ventilation. Blood samples (5 mL) from 
the left brachial artery were used for blood gas analysis. 
Body temperature was maintained at 37° to 37.7°C. A 
thoracotomy was performed via an incision along the left 
lateral edge of the keel to the first rib, with care taken to 
avoid the air sacs. The pericardium was opened to expose 
the left ventricle. A 4-0 prolene suture was looped loosely 
around a marginal branch of the left main coronary artery 
to permit coronary artery occlusion. 
After 30 min of recording, chickens were randomly al-
lotted to one of two treatment groups of 8 animals each. 
Controls received a 5-min intra-atrial infusion of 0.9% NaCl 
solution (2 mL/min) and experimental animals received 
the same infusion containing OK (100 µg·kg-1·min-1). Ten 
minutes after the end of infusion, 400 IU heparin was in-
jected, and 1 min later chickens were subjected to 60 min 
of coronary ischemia followed by 180 min of reperfusion. 
This protocol for the induction of myocardial ischemic injury 
has been previously used in rabbits (23). Reperfusion was 
validated by the return of the original color. Arterial pressure 
and heart rate were recorded throughout the experiment. 
After reperfusion, the heart was excised, the coronary 
artery ligature was retied, and the perfused myocardium was 
stained by perfusing black China ink through the aorta. The 
unstained region was denoted area at risk. The left ventricle 
with the septum was separated from surrounding tissue 
and cut from the apex to the base into 1-mm slices. Slices 
were incubated for 30 min at room temperature with 2,3,5-tri-
phenyltetrazolium chloride (1% in 0.1 M sodium phosphate 
buffer, pH 7.4) in order to stain viable tissue red, leaving the 
infarcted region pale. The slices were photographed, and 
left ventricular area, area perfused by the tied artery (area 
at risk), and infarcted area were quantified with the ImageJ 
program (National Institute of Health, USA).
Calculations and statistics
All quantitative data are reported as means ± SEM. 
The effect of the treatments on infarct size was compared 
by one-way ANOVA and post hoc t-tests with Bonferroni’s 
correction. Temporal changes in hemodynamic parameters 
within each group were tested by one-way repeated mea-
sures ANOVA followed by paired t-tests with Bonferroni’s 
correction. Since coronary flow in the Langendorff system 
was constant, changes in coronary vascular resistance 
were calculated from changes in perfusion pressure and 
were compared by one-way repeated measures ANOVA 
followed by paired t-tests with Bonferroni’s correction. Dif-
ferences were considered to be statistically significant at 
an error level of P < 0.05. 
Results 
The iv injection of OK produced a dose-dependent and 
large but transient fall in arterial pressure (Figure 1) and 
tachycardia. The 4-µg/kg dose increased heart rate from 
335 ± 38 to 402 ± 45 bpm (N = 5; P < 0.05). The kininase 
II inhibitor captopril (0.1 mg/kg, iv) potentiated the hypoten-
sion induced by 1 µg/kg OK (40 ± 6 vs 76 ± 10 mmHg, N 
= 5; P < 0.05). 
The injection of OK into the coronary circulation of 
Figure 1. Effect of iv injected ornitho-kinin on arterial pressure in 
the anesthetized chicken. Top, typical example. BK = bradykinin, 
20 µg/kg; OK = ornitho-kinin, 1 µg/kg; CAP = captopril, 0.1 mg/
kg, iv. Bottom, group data. Data are reported as means ± SEM 
for 6 animals each dose. *P < 0.05 vs no ornitho-kinin (ANOVA 
followed by the paired t-test).
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Figure 2. Effect of bolus injections of ornitho-kinin on coronary 
vascular resistance. The peptide was introduced into the per-
fusion medium as it entered the heart. Data are reported as 
means ± SEM for 6 animals each dose. *P < 0.05 vs no injec-
tion (ANOVA followed by the paired t-test).
Figure 3. Effect of pretreatment with ornitho-kinin on changes in 
arterial pressure and heart rate induced by coronary artery occlu-
sion (CAO) and reperfusion in anesthetized chickens. The long 
arrow indicates pretreatment (saline or ornitho-kinin, 500 µg/kg 
infused into the right ventricle for 5 min). Data are 1-min aver-
ages. Numbers on the X-axis indicate the following periods: 1 = 
just before the start of the experiment; 2 = in the middle of the 
period of infusion; 3 = just before CAO; 4 = at the end of 1 h of 
CAO; 5 = after 1 min of reperfusion, and 6-8 = after 1, 2, and 3 h 
of reperfusion, respectively. Data are reported as means ± SEM 
for 8 animals each dose. *P < 0.05 vs baseline (ANOVA followed 
by the paired t-test).
828 B.C. Prezoto et al.
www.bjournal.com.brBraz J Med Biol Res 42(9) 2009
perfused hearts caused an intense and concentration-
dependent vasodilation (Figure 2). OK did not significantly 
alter heart rate or systolic pressure (baseline: 154 ± 18 
bpm, 68 ± 5 mmHg, N = 5).
Figure 3 shows the cardiovascular changes that oc-
curred during cardiac ischemia and reperfusion. In control 
animals not injected with OK, occlusion of the left coronary 
artery significantly reduced arterial pressure. Upon release 
of the coronary ligature, pressure returned to pre-ischemic 
value, but tended to fall again during the reperfusion period, a 
fact possibly indicating the development of heart failure. The 
5-min infusion of OK reduced arterial pressure by almost 40 
mmHg. Arterial pressure fell significantly during occlusion of 
the coronary artery, but less than in controls, and pressure 
increased after release of the ligature, although it remained 
low throughout the rest of the experiment. 
The tied coronary artery supplied blood to about half the 
ventricular surface in both groups (controls: 48 ± 5%, OK-
pretreated: 58 ± 6%, difference not significant), indicating a 
constant placement of the coronary ligature. In the control 
group pretreated with 0.9% saline solution, ischemia fol-
lowed by reperfusion caused a large myocardial infarct (35 
± 3% of the area perfused by the tied artery). Infarct size 
was reduced to 10 ± 2% by pretreatment with OK (P < 0.05) 
(Figure 4). Smaller doses of OK (25, 50, and 75 µg·kg-1·min-1 
for 5 min, N = 4 each) failed to reduce infarct size. 
Discussion 
Blockade of the left coronary artery followed by 3 h of 
reperfusion reliably caused an infarct in chickens. This is 
consistent with in vitro studies on a Langendorff prepara-
tion showing that ischemia can produce myocardial injury 
in pigeons (18). Features of the in vivo method used by 
us included little variation in the area perfused by the tied 
artery (area at risk of about 50% of the left ventricular wall), 
and an infarct size of about 30% of the area at risk, also 
with little variation. Arterial pressure fell during the period 
of ischemia, suggesting developing heart failure, similar to 
the changes seen in mammals. 
Figure 4. Effect of pretreatment with ornitho-kinin (500 µg/kg 
perfused for 5 min) on infarct size induced by coronary artery oc-
clusion in anesthetized chickens. Top, Section of a triphenyltetra-
zolium chloride-stained wall of the left ventricle with healthy (red) 
and infarcted (pale) tissue. Data are reported as means ± SEM in 
the bar graph for 8 animals each dose. *P < 0.05 vs saline control 
(ANOVA and post hoc t-tests with Bonferroni’s correction).
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OK caused a short-lasting vasodilation in the heart and 
the rest of the body, indicating that OK receptors are pres-
ent in the chicken, in agreement with previous data (24). 
The potentiation of the effect of OK by captopril indicates 
that chickens contain kininases. Even large amounts of 
BK failed to induce hypotension in chickens, in agreement 
with an earlier finding that this mammalian peptide fails to 
contract the pigeon uterus (25). This indicates that birds 
may have developed their own KKS that generates a kinin 
structurally different from mammalian BK with appreciably 
different bioactivity.
In mammals, infusion of BK has been shown both to 
protect isolated hearts subjected to local ischemia/reperfu-
sion and to be an important mediator of the beneficial effect 
of ischemic preconditioning (26). We found that OK also 
protected against ischemic heart damage. The dose of 
OK used by us (500 µg/kg in 5 min) was chosen because 
it reduced blood pressure without inducing cardiovascular 
collapse. One possible explanation for the need for these 
higher doses injected systemically is that the generation of 
Lys-BK occurs locally during episodes of acute ischemia 
(4) and the local concentration of Lys-BK is relatively high, 
improving adequate receptor binding. Whether or not this 
dose is the same as the level of OK at cardiac receptors 
during ischemic preconditioning is not known, but it is lower 
than the dose of BK necessary to induce cardiac precondi-
tioning in rabbits (1250 µg/kg in 5 min) (26). Since the effect 
of ischemic preconditioning in rabbits was blocked with the 
BK receptor antagonist HOE 140 (26), it appears that this 
infusion resulted in levels of BK at the cardiac receptors 
similar to those that occur in vivo in ischemic precondition-
ing. No drugs are known to block OK receptors: the potent 
mammalian B2 receptor antagonist, HOE 140, acts as an 
OK receptor agonist (24).
From these experiments, it became apparent that a 
functional but qualitatively different KKS (PK, HK, OK spe-
cific receptors) is present in chickens. The cardioprotective 
activity of OK in our acute anesthetized, open-chest chicken 
model of acute coronary occlusion suggests the presence 
of a functioning cardiac kallikrein kinin system. This finding 
challenges current studies on mammals connecting this 
cardioprotective action of the cardiac KKS to cleavage of 
LK by TK (1), since LK seems to be absent from the plasma 
of this animal species (15). 
We propose the chicken as an experimental model suit-
able for studying several open questions concerning the 
physiological role of the KKS. These include: i) how PK is 
activated in vivo in the mammalian contact system. Several 
studies have reported the in vivo activation of PK either as 
dependent on (27) or independent of FXII (28). Since FXII is 
not present in avian plasma, alternative mechanisms of PK 
activation independent of FXII can be investigated in birds; 
ii) the selectivity of kallikreins for specific substrates, as seen 
in mammals (PK for HK and TK for LK), is not possible in 
the plasma of chickens since only HK was detected in this 
species (15). The possibility of HK cleavage by TK opens 
alternative routes for kininogen cleavage, and may help to 
understand the physiological roles of LK; iii) in mammals, 
the mechanism of FXI activation in vivo during hemostasis 
remains polemic, and both platelet/FXII-dependent (29,30) 
and FXII-independent (31) mechanisms have been pro-
posed. Thrombocytes are homologous in function to mam-
malian platelets, playing a role similar to these cells with 
regard to aggregation and clot formation (32,33). Therefore, 
the activation of FXI by thrombocytes can be studied in 
birds in the absence of FXII, and iv) although FXII is not 
involved in hemostasis, there is a debate about whether 
it plays a key role in abnormal hemostasis or thrombosis. 
FXII-deficient mice fail to develop thrombosis in response 
to vessel injury and consequently FXII could be an ideal 
target for safe anticoagulation (7). 
Transgenic and gene-targeting technologies allow-
ing the generation of genetically altered animal models 
have greatly advanced our understanding of the function 
of specific genes. This is also true for the KKS, in which 
some, but not yet all, components have been functionally 
characterized using such techniques. The first genetic 
change in the KKS was found in a brown Norway rat that 
had a natural mutation that inactivated the kininogen gene. 
Mice deficient in or overexpressing TK, B1 and B2 recep-
tors are accessible today. There is still no animal model 
with genetic alterations of PK, kininases I and some other 
degrading enzymes (34).
In conclusion, in addition to specific receptor blockers 
and genetically modified mouse models, this FXII-deficient 
animal model supplied by nature can help unravel the roles 
of the intertwined branches of the KKS and the physiological 
and pathophysiological roles of FXII, TK and LK in hemo-
stasis, thrombosis and in the cardiovascular system.
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